Researchers from Pritzker Molecular Engineering, under the guidance of Prof. Jeffrey Hubbell, demonstrated that their compound can eliminate the autoimmune response linked to multiple sclerosis. Researchers at the University of Chicago's Pritzker School of Molecular Engineering (PME) have developed

Researchers from Pritzker Molecular Engineering, under the guidance of Prof. Jeffrey Hubbell, demonstrated that their compound can eliminate the autoimmune response linked to multiple sclerosis. Researchers at the University of Chicago’s Pritzker School of Molecular Engineering (PME) have developed

    • holycrap@lemm.eeEnglish
      9·
      1 year ago

      I’ll come back in a few hours when I’m on my computer and give you the list. I’m sure others will be interested in it as well.

        • holycrap@lemm.eeEnglish
          3·
          1 year ago

          I posted more information above in this comment: https://lemm.ee/comment/3624282

          TAK-101 is a celiac variant of a (currently paused) MS vaccine. I linked a video on that in my other post that may interest you. The video predates the decision to focus on just one disease. Basically the first iteration of their technology wasn’t effective, but based on the theory that if it works on one autoimmune disease it should work on all of them, they’ve switched their focus to celiac because it’s easier to test the efficacy. Just measure the amount of IL-2 during a gluten exposure. Also it’s cheaper to run one trial than the 5 they had before for various diseases.

          The good news is progress is being made on this. But don’t expect it any time soon until you can actually book an appointment to get the procedure.

          • MajesticSloth@lemmy.worldEnglish
            1·
            1 year ago

            Thank you. I appreciate you taking the time to respond with more info.

            I wasn’t expecting much so no worries and not expecting anything soon. I’ve seen these things for a couple decades now. But this one is interesting. So again thank you.